Cleerly was 17 days away from running out of cash during COVID-19
Dr. Jim · He raised $300M to prevent heart attacks. Here's how he got his health tech startup off the groun... · PMF Show · Apr 14, 2025 · at 39:40
Dr. James Min, founder and CEO of Cleerly, recounts near-death experiences and funding crises in the company's history.
0:00 / 0:05exact quote · 5.2s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“I mean, during the pandemic, right, like, we were 17 days away from being out of operating capital.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Dr. Jim
Not all arterial plaque is bad: stable plaque actually protects you
“We learned that not all plaque is bad. In fact, that some plaques are extremely dangerous for you and the strongest predictors of who will have a heart attack and others are actually Very stable and almost protected against having a heart attack in the future.”
The first symptom of heart disease is often a catastrophic event
“The most common presentation for having heart disease like that is not presenting with chest pain or shortness of breath, but it's simply having a catastrophic event, dying of a heart attack or suffering a heart attack at home with no antecedent warning.”
90% of heart attacks are preventable with existing medical treatments
“90% of heart attacks are preventable. We, it's not that we lack the treatments. It's that we're just not identifying people soon enough so that we can prevent these events from happening.”
Heart medications don't eliminate plaque; they transform it into stable protective plaque
“And what we found was that the medicines, they didn't make plaque go away per se. They just transformed that plaque from the good to the, from the bad to the good plaque over time, and that was the mechanism of stabilization.”
Cleerly is running a 7,500-patient RCT on asymptomatic screening
“We're doing a large-scale randomized control trial right now. It's about 7500 patients. We're a little over 2000 patients enrolled, and the purpose of this trial is to test the hypothesis that image-guided care, clearly guided care, is superior to conventional…”